An experimental evaluation of drug-induced mutational meltdown as an antiviral treatment strategy
- PMID: 27566611
- DOI: 10.1111/evo.13041
An experimental evaluation of drug-induced mutational meltdown as an antiviral treatment strategy
Abstract
The rapid evolution of drug resistance remains a critical public health concern. The treatment of influenza A virus (IAV) has proven particularly challenging, due to the ability of the virus to develop resistance against current antivirals and vaccines. Here, we evaluate a novel antiviral drug therapy, favipiravir, for which the mechanism of action in IAV involves an interaction with the viral RNA-dependent RNA polymerase resulting in an effective increase in the viral mutation rate. We used an experimental evolution framework, combined with novel population genetic method development for inference from time-sampled data, to evaluate the effectiveness of favipiravir against IAV. Evaluating whole genome polymorphism data across 15 time points under multiple drug concentrations and in controls, we present the first evidence for the ability of IAV populations to effectively adapt to low concentrations of favipiravir. In contrast, under high concentrations, we observe population extinction, indicative of mutational meltdown. We discuss the observed dynamics with respect to the evolutionary forces at play and emphasize the utility of evolutionary theory to inform drug development.
© 2016 The Author(s). Evolution © 2016 The Society for the Study of Evolution.
Similar articles
-
The mechanism of resistance to favipiravir in influenza.Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):11613-11618. doi: 10.1073/pnas.1811345115. Epub 2018 Oct 23. Proc Natl Acad Sci U S A. 2018. PMID: 30352857 Free PMC article.
-
The Combined Effect of Oseltamivir and Favipiravir on Influenza A Virus Evolution.Genome Biol Evol. 2017 Jul 1;9(7):1913-1924. doi: 10.1093/gbe/evx138. Genome Biol Evol. 2017. PMID: 28854600 Free PMC article.
-
Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis.Antimicrob Agents Chemother. 2016 Oct 21;60(11):6679-6691. doi: 10.1128/AAC.01156-16. Print 2016 Nov. Antimicrob Agents Chemother. 2016. PMID: 27572398 Free PMC article.
-
[Favipiravir, a new concept of antiviral drug against influenza viruses].Rev Esp Quimioter. 2017 Apr;30(2):79-83. Epub 2017 Feb 8. Rev Esp Quimioter. 2017. PMID: 28176519 Review. Spanish.
-
Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Antiviral Res. 2013 Nov;100(2):446-54. doi: 10.1016/j.antiviral.2013.09.015. Epub 2013 Sep 29. Antiviral Res. 2013. PMID: 24084488 Free PMC article. Review.
Cited by
-
Mutations in Influenza A Virus Neuraminidase and Hemagglutinin Confer Resistance against a Broadly Neutralizing Hemagglutinin Stem Antibody.J Virol. 2019 Jan 4;93(2):e01639-18. doi: 10.1128/JVI.01639-18. Print 2019 Jan 15. J Virol. 2019. PMID: 30381484 Free PMC article.
-
Oral Favipiravir Exposure and Pharmacodynamic Effects in Adult Outpatients With Acute Influenza.J Infect Dis. 2024 Aug 16;230(2):e395-e404. doi: 10.1093/infdis/jiad409. J Infect Dis. 2024. PMID: 37739792 Free PMC article. Clinical Trial.
-
Favipiravir in Therapy of Viral Infections.J Clin Med. 2021 Jan 13;10(2):273. doi: 10.3390/jcm10020273. J Clin Med. 2021. PMID: 33451007 Free PMC article. Review.
-
Resistance of Echovirus 11 to ClO2 Is Associated with Enhanced Host Receptor Use, Altered Entry Routes, and High Fitness.Environ Sci Technol. 2017 Sep 19;51(18):10746-10755. doi: 10.1021/acs.est.7b03288. Epub 2017 Sep 8. Environ Sci Technol. 2017. PMID: 28837336 Free PMC article.
-
US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19.Open Forum Infect Dis. 2021 Dec 7;8(12):ofab563. doi: 10.1093/ofid/ofab563. eCollection 2021 Dec. Open Forum Infect Dis. 2021. PMID: 34888401 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources